revenu high end guidanc exclud adjust
rel forecast us breast prostat revenu line ou littl
light top bottom line guidanc set street rais pt
ghdx look well posit growth howev believ may
alreadi captur current valuat
revenu forecast exclud
portfolio adjust revenu would line forecast
high end previou guidanc rang us breast
prostat revenu line forecast ex ou revenu
light due slightli lower expect
gross margin line forecast exclud impact
oper margin forecast driven better expect revenu
lower expect expens ep forecast
consensu high end guidanc
revenu guid y/i seemingli line
previou soft guidanc doubl digit revenu growth ghdx issu last month link
note midpoint revenu guidanc street
follow addit compon guidanc provid gross margin
street oper expens growth y/i adjust
ebitda oper margin reiter non-gaap net incom
non-gaap ep midpoint
even absent portfolio adjust better expect close
outlook encourag well strong top bottom line
guidanc set street
believ high end guidanc achiev impli msd-hsd volum
growth us breast driven tailorx momentum target market
revenu growth prostat led improv public commerci reimburs
increment revenu german reimburs drive strong ou
revenu growth second half
rais price target arriv use blend
combin rel multipl premium peer group ev/ebitda
dcf note still current level view outlook
robust top line growth combin potenti materi margin expans
attract continu look compel entri point
pleas see page report import disclosur
genom health uniqu clinic research regulatori reimburs expertis
one establish leader cancer-focus advanc genet genom
diagnost market fulli believ promis advanc genom genet
diagnost expect genom remain lead develop provid
complex genet diagnost servic year come subsequ year stock
under-perform believ combin acceler revenu increas
confid pipeline/ second act potenti oper break-even posit
ghdx revenu multipl upsid
prostat reimburs coverag
colon penetr acceler
absenc chemotherapi benefit label
bit limit
prostat provid meaning sourc
revenu next sever year
privat payer expand
coverag expand prostat revenu
ou growth continu acceler
materi growth breast
indic colon fail materi
genom health focus develop commerci clinic laboratori
test servic aim help physician patient make individu cancer
genom analysi tumor biopsi specimen provid tumor-specif inform genom
launch first test oncotyp dx breast cancer aid predict
likelihood cancer recurr likelihood chemotherapi benefit earli stage
breast cancer patient beyond breast cancer oncotyp dx colon cancer launch
oncotyp dx prostat cancer launch may
compani report thomson eikon cowen compani
cowen vs consensu mm except revenu high end anticip adjust gross margin reiter oper revenu metric mm except growth invas breast revenu growth volum growth prostat revenu growth volum growth colon dci growth growth statement mm except per y/i nmnmnmnmshare count expens forecast percentag sale increas q/q like driven headcount ep forecast consensu high end guidanc oper margin forecast us invas breast revenu forecast manag note adjust quarter primarili invas breast absent revenu would line forecast notabl volum growth slightli higher forecast close year us revenu forecast detail provid expens forecast percentag sale non-gaap reconcili includ biocarti adjust prostat revenu line forecast volum growth lower expect off-set improv like commerci payer side revenu forecast exclud portfolio adjust revenu would line forecast high end previou guidanc rang us invas breast prostat revenu line forecast exclud ou revenu light gross margin forecast consensu ad quarter commentari provid like came line forecast ou revenu forecast volum growth line forecast came slightli light like volatil advanc broad coverag cowen
compani report cowen compani
mm except test cagrcommentsrevenu datatot revenu guidanc dd revenu growth product product growth high end guidanc assum y/i revenu growth product growth product growth fxn impact impact product datatest high end guidanc assum y/i volum growth geographi unit test total total total total datatot revenue/test price us cowen
compani report thomson eikon cowen compani
mm except per share revenu guidanc dd revenu target year revenu compound-annual-growth-rate anticip adjust gross margin sale sale sale oper sale grow oper expens adjust ebitda target oper margin target oper incom reiter increment non-oper interest non-gaap net incom per non-gaap ep base share dilut except per share gross op consensu estim cowen
price target base sever methodolog may includ analysi market risk
group ev/ebitda premium discount averag group price-to-earnings sum part net asset
valu dividend return return equiti roe next month
risk medic life scienc tool sector may includ reduct delay research
develop budget govern fund reduc delay purchas
health care hospit custom increas extend regulatori hurdl process
regul product increas depend volatil emerg market revenu
profit gener macroeconom challeng
make invest recommend earli stage pre-commerci ls dt
compani base upon assess technolog probabl market success
competit regulatori reimburs etc potenti market opportun
event success howev compani lack tradit and/or matur
financi metric believ good methodolog assign specif
target price stock
risk includ limit reimburs cut test price delay weaker-
than-expect clinic data support new product competit result market
share eros weaker-than-expect uptak intern market deliv
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock genom health secur
cowen compani llc manag co-manag public offer past month
cowen compani llc receiv compens invest bank servic past month
past month client cowen compani llc cowen compani llc provid provid invest bank servic
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
inform herein base sourc believ reliabl guarante us purport complet statement summari avail data
opinion express herein statement judgment date subject chang without notic opinion recommend herein take
account individu client circumst object need intend recommend invest strategi recipi report must make
independ decis regard secur subject research report case secur financi instrument may difficult valu sell reliabl
inform valu risk relat secur financi instrument may difficult obtain extent report discuss legal proceed issu
prepar express intend express legal conclus opinion advic salespeopl trader profession may provid oral written
market commentari trade strategi client reflect opinion contrari opinion express research princip trade area invest
busi may make invest decis inconsist recommend view express research cowen compani llc maintain physic electron
procedur inform barrier address flow inform among depart within cowen compani llc order prevent avoid conflict
interest respect analyst recommend
import disclosur regard compani subject research report pleas contact complianc depart cowen compani llc lexington
avenu floor new york ny addit import disclosur except valuat method risk avail firm disclosur
websit http //cowen bluematrix com/sellside/disclosur action
equiti research price target cowen compani llc assign price target compani cover equiti research unless note otherwis equiti research price target
issuer stock repres valu analyst reason expect stock reach perform period twelv month price target equiti secur
report consid context prior publish cowen compani llc equiti research report includ disclosur equiti report
firm disclosur websit may may includ equiti research price target well develop relat issuer industri financi market
equiti research price target valuat methodolog risk associ achiev given equiti research price target pleas see analyst equiti research report
publish target
cowen cross-asset research due natur fix incom market issuer debt secur issuer discuss cowen cross-asset research report
assign rate price target may continu follow accordingli investor must regard brand report provid stand-alon analysi reflect
analyst opinion date report expect continu analysi addit report relat issuer debt secur issuer
time time cowen cross-asset research analyst provid invest recommend secur subject report recommend intend
time date public within paramet specifi individu report cowen cross-asset research invest recommend made
strictli case-by-cas basi recommend provid part overarch rate system set consist appli benchmark view express
cross-asset research report may differ view offer firm equiti research report prepar client
notic uk investor public produc cowen compani llc regul unit state finra commun person kind
describ articl servic market act promot order must transmit person without
notic european union investor individu produc recommend requir obtain certain licens financi regulatori author finra review
author current licens statu histori employ histori report regulatori custom disput crimin matter via brokercheck finra http //
brokercheck finra org/ individu licens statu finra constru endors finra gener biograph inform also avail
research analyst www cowen com
addit complet preced recommend histori relat recommend research report avail http //cowen bluematrix com/sellside/
recommend contain report produc februari et dissemin februari et
copyright user agreement gener inform relat report
cowen compani llc right reserv member nyse finra sipc research report prepar exclus use cowen client may
reproduc display modifi distribut transmit disclos whole part form manner other outsid organ without express prior
written consent cowen cowen research report distribut simultan client elig receiv research report unauthor use disclosur
